In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market. Pfizer doesn't need a total victory to make things harder ...

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...

How AbbVie’s Humira Still Reigns, Despite New Competition Quarterly revenue for blockbuster arthritis drug declines, largely because of discounts for middlemen By David Wainer July 27, 2023 11: ...

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

AbbVie expects Botox's market share in the aesthetics space to remain strong even as rivals launch competing anti-wrinkle injections, a company executive said on Wednesday.

Revenue at North Chicago-based AbbVie dove by nearly 10% during the first few months of this year — a drop that comes as its bestselling drug Humira faces competition for the first time in the U.S.